Among the nine small molecules with MAP2K7 inhibitory capacity described in the literature, only four were evaluated in cancer models, predominantly multiple melanoma and T-cell acute lymphoblastic leukemia, and three were assessed in mouse models. This evidence concerns the gene MAP2K7 and T-cell acute lymphoblastic leukemia.